Saturday, May 25, 2019

Longas Launches, Unveiling Morphoseq Long Read DNA Sequencing Technology

BWW News Desk
May 16, 2019

Longas Technologies Pty Ltd Longas a developer of Next Generation Sequencing NGS technologies today emerges from stealth mode unveiling its Morphoseq technology and announcing the appointment to CEO of Nick McCooke who built and led the team at Solexa that pioneered NGS prior to the company being acquired by Illumina pblockquotep idpullquotepblockquote p Morphoseq is a disruptive technology designed to dramatically improve the performance of industrystandard NGS platforms by increasing effective read lengths with benefits in accuracy and cost efficiency It was developed over the last few years by a team led by worldleading computational biologist Professor Aaron Darling CSO at Longas Morphoseq converts short read sequencers into virtual long read sequencers enabling finishedquality genome assemblies with high accuracy including resolution of difficulttoassemble genomic regions Longas has an extensive portfolio of international patent filings covering the Morphoseq technology p p Longas is a spin out from the ithree institute at the University of Technology Sydney UTS funded by Australias Medical Research Commercialisation Fund MRCF and investment from the Companys founders and directors In addition to Professor Aaron Darling cofounders from UTS include Dr Catherine Burke and Professor Ian Charles previously Director of the ithree institute and now Director of the Quadram Institute UK p p The rise of highthroughput low cost DNA sequencing has made genome sequencing routine and affordable but has come at the cost of read length explains Longas cofounder and CSO Professor Aaron Darling It is very difficult for assembly methods to resolve genomic repeats that are longer than the read length But long repeats are present at many of the most clinically informative parts of genomes such as drug resistance genes in bacteria and the MHC locus in humans The ability to accurately assemble and phase these into individual chromosomes for humans and microorganisms has important clinical and epidemiological applications p p Nick McCooke who has been a nonexecutive director of the company since 2015 has taken on the role of CEO to lead commercialization and industry partnering As founding CEO of Solexa he took the company from spinout to its NASDAQ listing in 2005 He led the development of the worlds leading NGS technology which became the basis of Illuminas NGS product line Currently pursuing a portfolio career with a focus on disruptive genomics technologies he is also a NonExecutive Director of Evonetix Ltd and Bioventix plc Prior board and leadership positions in the UK Belgium USA and Japan include DNA Electronics inventor of semiconductor sequencing Biogazelle Oxford Cancer Biomarkers Pronota Solexa Rapigene Innovex Quintiles and Celltech as well as a Trustee of the Association of Medical Research Charities Nick has an MBA from London Business School and is a graduate in engineering p p Commenting on the investment in the new Company Dr Stephen Thompson Chairman of Longas and Managing Director at Brandon Capital the venture capital firm that manages the MRCF said Longas is an exciting opportunity that could help transform the research epidemiology and clinical genomics fields Its technology solves a key problem in NGS and promises to have an important impact within the NGS market a market that is expected to grow from US57 billion last year to US20 billion by 2025 p p CEO Nick McCooke added As its speed and accuracy increases and cost reduces DNA sequencing is having a massive impact in a wide number of fields There is an expanding opportunity for technologies that work in tandem with the main sequencing platforms improving key aspects of their performance p p Details of the Morphoseq technology will be presented during the iSequencing Finishing and Analysis in the Future imeeting May 21 23 Santa Fe NM USA The presentation by Professor Aaron Darling CSO entitled iIntroducing Morphoseq high accuracy long reads from short read platformsi is on 21 May 2019 at 430pm MDT 22 May 830am Sydney p p classbwalignc Ends p p For full press release and notes to editors please click a referrerpolicyunsafeurl targetblank hrefhttpsctsbusinesswirecomctCTidsmartlinkampurlhttp3A2F2Flongastechcom2Fampesheet51985473ampnewsitemid20190515005853amplanenUSampanchorhereampindex1ampmd5588c726c9dec2ebe12c41c134b15243b relnofollowherea p p p pimg referrerpolicyunsafeurl alt srchttpsctsbusinesswirecomctCTidbwnewsampsty20190515005853r1ampsidweb01ampdistronxamplangen stylewidth0height0span classbwct31415p

SOURCE: BUSINESS WIRE. ©2015 Business Wire

Comments

Registration Login
Registration Login
Registration Login
Registration